Reports Q4 revenue $2.54B, consensus $2.44B. Biogen President and CEO Christopher Viehbacher said: "Strategically, we are working to put Biogen on a sustainable growth trajectory as we execute on two important near-term opportunities with LEQEMBI in Alzheimer’s disease and zuranolone in depression, further diversify our product portfolio, and seek expansion through organic and external opportunities, including new partnerships. I believe we have a solid foundation on which to build Biogen’s future, including strong internal talent with a passion for making a difference for patients."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Notable companies reporting before tomorrow’s open
- Hyperfine could have ‘interesting’ opportunity in Alzheimer’s, says Evercore ISI
- Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
- Biogen, Sage Therapeutics: FDA accepts NDA for zuranolone
- Eisai, Biogen say lecanemab received Priority Review status in Japan
